scholarly journals Insulin-Like Growth Factor Binding Protein-Related Protein 1 (IGFBP-rP1/MAC25) Is Linked to Endothelial-Dependent Vasodilation in High-Ferritin Type 2 Diabetes

Diabetes Care ◽  
2007 ◽  
Vol 30 (6) ◽  
pp. 1615-1617 ◽  
Author(s):  
A. Lopez-Bermejo ◽  
J. Khosravi ◽  
W. Ricart ◽  
A. Castro ◽  
V. Hwa ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Growth Factor ◽  
Binding Protein ◽  
Insulin Like Growth Factor ◽  
Related Protein ◽  
Factor Binding

scholarly journals Insulin-like growth factor-binding protein-1 in the prediction and development of type 2 diabetes in middle-aged Swedish men

Diabetologia ◽  
2008 ◽  
Vol 51 (7) ◽  
pp. 1135-1145 ◽  
Author(s):  
M. S. Lewitt ◽  
A. Hilding ◽  
C.-G. Östenson ◽  
S. Efendic ◽  
K. Brismar ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Growth Factor ◽  
Binding Protein ◽  
Insulin Like Growth Factor ◽  
Middle Aged ◽  
Factor Binding

scholarly journals Insulin-Like Growth Factor Binding Protein 2 (IGFBP-2) and the Risk of Developing Type 2 Diabetes

Diabetes ◽  
2018 ◽  
Vol 68 (1) ◽  
pp. 188-197 ◽  
Author(s):  
Clemens Wittenbecher ◽  
Meriem Ouni ◽  
Olga Kuxhaus ◽  
Markus Jähnert ◽  
Pascal Gottmann ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Growth Factor ◽  
Binding Protein ◽  
Insulin Like Growth Factor ◽  
Factor Binding

scholarly journals Increased DNA methylation levels of the insulin-like growth factor binding protein 1 gene are associated with type 2 diabetes in Swedish men

2013 ◽  
Vol 5 (1) ◽  
Author(s):  
Tianwei Gu ◽  
Harvest F Gu ◽  
Agneta Hilding ◽  
Louise K Sjöholm ◽  
Claes-Göran Östenson ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Dna Methylation ◽  
Growth Factor ◽  
Binding Protein ◽  
Insulin Like Growth Factor ◽  
Factor Binding

scholarly journals Insulin-like growth factor binding protein 2 (IGFBP-2) and the risk of developing type 2 diabetes

2019 ◽  
Author(s):  
M Ouni ◽  
C Wittenbecher ◽  
O Kuxhaus ◽  
M Jaehnert ◽  
M Schulze ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Growth Factor ◽  
Binding Protein ◽  
Insulin Like Growth Factor ◽  
Factor Binding

Fasting c-peptide and insulin-like growth factor-binding protein-1 levels help to distinguish childhood type 1 and type 2 diabetes at diagnosis

2007 ◽  
Vol 8 (2) ◽  
pp. 53-59 ◽  
Author(s):  
Lorraine E Levitt Katz ◽  
Abbas F Jawad ◽  
Jaya Ganesh ◽  
Máire Abraham ◽  
Kathryn Murphy ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Growth Factor ◽  
Binding Protein ◽  
Insulin Like Growth Factor ◽  
C Peptide ◽  
Factor Binding ◽  
Childhood Type

scholarly journals Insulin-like Growth Factor Binding Protein-7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study

2020 ◽  
Author(s):  
James L. Januzzi Jr ◽  
Javed Butler ◽  
Naveed Sattar ◽  
Jialin Xu ◽  
Wayne Shaw ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Risk ◽  
Growth Factor ◽  
Binding Protein ◽  
Insulin Like Growth Factor ◽  
High Cardiovascular Risk ◽  
Factor Binding ◽  
Assessment Study ◽  
Cardiovascular Assessment

<b>Objective</b>: To analyze the association between concentrations of plasma insulin-like growth factor binding protein-7 (IGFBP7) with renal and cardiac outcomes among participants with type 2 diabetes and high cardiovascular risk. <p><b>Research Design and Methods</b>: Associations between IGFBP7 levels and clinical outcomes were assessed among participants in the Canagliflozin Cardiovascular Assessment Study (CANVAS) with type 2 diabetes and high cardiovascular risk. </p> <p><b>Results</b>: Among CANVAS participants, 3577 and 2898 had IGFBP7 measured at baseline and 1 year, respectively. Per log-unit higher concentration, baseline IGFBP7 was significantly associated with the composite renal endpoint of sustained 40% reduction in eGFR, need for renal replacement therapy, or renal death (hazard ratio [HR]=3.51; <i>P</i><0.001), and the composite renal endpoint plus cardiovascular death (HR=4.90; <i>P</i><0.001); other outcomes including development or progression of albuminuria were also predicted by baseline IGFBP7. <a>Most outcomes were improved by canagliflozin regardless of baseline IGFBP7; however, those with baseline concentrations ≥96.5 ng/mL appeared to benefit more from canagliflozin relative to first progression of albuminuria compared to those with lower baseline IGFBP7 (HR=0.64 vs 0.95; <i>P</i><sub>interaction </sub>=0.003). </a>Canagliflozin did not lower IGFBP7 concentrations by 1 year; however, at 1 year, higher IGFBP7 concentrations more strongly predicted the composite renal endpoint (HR=15.7; <i>P</i><0.001). Patients with rising IGFBP7 between baseline to 1 year had the highest number of composite renal events. </p> <p><b>Conclusions</b>: <a>Plasma IGFBP7 concentrations predicted renal and cardiac events among participants with type 2 diabetes and high cardiovascular risk. More data are needed regarding circulating IGFBP7 and progression of diabetic kidney disease and its complications. </a></p>

Sign in / Sign up

Export Citation Format

Share Document